Health-related quality of life (HRQoL) in AVAglio, a randomized, placebo (P)-controlled phase III study of bevacizumab (B), temozolomide (T) and radiotherapy (RI) in patients (pts) with newly diagnosed glioblastoma (GBM)

被引：0
|
作者：
Bottomley, A. [1 ]
Henrikkson, R. [2 ,3 ]
Taphoorn, M. J. B. [4 ,5 ]
Cloughesy, T. [6 ]
Wick, W. [7 ]
Mason, W. [8 ]
Saran, F. [9 ]
Nishikawa, R. [10 ]
Ravelo, A. [11 ]
Chinot, O. L. [12 ]
机构：
[1] EORTC, Qual Life Dept, Brussels, Belgium
[2] Reg Canc Ctr Stockholm, Stockholm, Sweden
[3] Umea Univ, Dept Radiotherapy & Oncol, Stockholm, Sweden
[4] Med Ctr Haaglanden Hague, Amsterdam, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands
[6] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA
[7] Univ Med Ctr, Dept Neurooncol, Heidelberg, Germany
[8] Univ Toronto, Princess Margaret Hosp, Fac Med, Toronto, ON, Canada
[9] Royal Marsden NHS Fdn Trust, Neurooncol Unit, Sutton, Surrey, England
[10] Saitama Med Univ, Dept Neurooncol Neurosurg, Int Med Ctr, Saitama, Japan
[11] Genentech Inc, Clin Pharmacol, San Francisco, CA 94080 USA
[12] Aix Marseille Univ, CHU Timone, AP HM, Serv Neurooncol, Marseille, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3316
引用
收藏
页码：S780 / S780
页数：1
相关论文
共 50 条
  • [31] A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548
    Weller, Michael
    Lim, Michael
    Idbaih, Ahmed
    Steinbach, Joachim
    Finocchiaro, Gaetano
    Raval, Raju
    Ashby, Lynn
    Ansstas, George
    Baehring, Joachim
    Taylor, Jennie
    Honnorat, Jerome
    Petrecca, Kevin
    De Vos, Filip
    Wick, Antje
    Sumrall, Ashley
    Roberts, Mustimbo
    Slepetis, Ruta
    Warad, Deepti
    Lee, Michelle
    Reardon, David
    Omuro, Antonio
    NEURO-ONCOLOGY, 2021, 23 : 55 - 56
  • [32] Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study
    Dieras, V.
    Arun, B.
    Han, H. S.
    Wildiers, H.
    Friedlander, M.
    Ayoub, J. P.
    Puhalla, S.
    Hudgens, S.
    Floden, L.
    Khandelwal, N.
    Benjamin, K.
    Kamalakar, R.
    Maag, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S348 - S349
  • [33] Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC)
    Jiang, Di Maria
    Wong, Bryan
    Morgans, Alicia K.
    Sweeney, Christopher
    Fizazi, Karim
    Chi, Kim N.
    Powles, Thomas
    Perlis, Nathan
    Kulkarni, Girish S.
    Sridhar, Srikala S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Joint EORTC brain tumour group/radiotherapy group and NCIC CTG phase III randomized controlled trial evaluating health-related quality of life in glioblastoma patients
    Taphoorn, Martin J.
    Stupp, Roger
    Osoba, David
    Curschmann, Juergen
    Kortmann, Rolf
    van den Bent, Martin
    Mason, Warren
    Coens, Corneel
    Eisenhauer, Elizabeth
    Bottomley, Andrew
    ANNALS OF ONCOLOGY, 2004, 15 : 206 - 206
  • [35] Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic urothelial carcinoma (mUC)
    Jiang, Di Maria
    Wong, Bryan
    Bellmunt, Joaquim
    Powles, Thomas
    Morgans, Alicia K.
    Vaughn, David J.
    Sridhar, Srikala S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [36] Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) plus chemotherapy followed by vel maintenance (maint)
    Cella, D.
    Bookman, M.
    Steffensen, K. Dahl
    Coleman, R. L.
    Dinh, M.
    Khandelwal, N.
    Benjamin, K.
    Kamalakar, R.
    Sullivan, D.
    Floden, L.
    Hudgens, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S612 - S612
  • [37] Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance)
    Laack, Nadia N.
    Galanis, Evanthia
    Anderson, S. Keith
    Leinweber, Clinton
    Buckner, Jan C.
    Giannini, Caterina
    Geoffroy, Francois J.
    Johnson, Derek Richard
    Lesser, Glenn Jay
    Jaeckle, Kurt A.
    Sarkaria, Jann Nagina
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Health-related quality of life (HRQOL) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Results from the first trial.
    Delforge, Michel
    Minuk, Leonard
    Eisenmann, Jean-Claude
    Arnulf, Bertrand
    Canepa, Letizia
    Fragasso, Alberto
    Leyvraz, Serge
    Langer, Christian
    Ezaydi, Yousef
    Vogl, Dan T.
    Giraldo-Castellano, Pilar
    Yoon, Sung-Soo
    Martins, Angelo
    Zarnitsky, Charles
    Barbe, Martine Escoffre
    Lemieux, Bernard
    Proskorovsky, Irina
    Ervin-Haynes, Annette L.
    Houck, Vanessa
    Facon, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Health-Related Quality of Life in Elderly Patients With Newly Diagnosed Glioblastoma Treated With Short-Course Radiation Therapy Plus Concomitant and Adjuvant Temozolomide
    Minniti, Giuseppe
    Scaringi, Claudia
    Baldoni, Alessandra
    Lanzetta, Gaetano
    De Sanctis, Vitaliana
    Esposito, Vincenzo
    Enrici, Riccardo Maurizi
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (02): : 285 - 291
  • [40] Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial
    Silvia G. R. Verelst
    F. Termorshuizen
    C. A. Uyl-de Groot
    M. R. Schaafsma
    A. H. M. Ammerlaan
    S. Wittebol
    H. A. M. Sinnige
    S. Zweegman
    M. van Marwijk Kooy
    R. van der Griend
    H. M. Lokhorst
    P. Sonneveld
    P. W. Wijermans
    Annals of Hematology, 2011, 90 : 1427 - 1439
12345